The development of novel therapies for rheumatoid arthritis

Bibliography

• Firestein GS. Xxxxx. In: Harris ED, Genovese MC, Firestein GS, Sargent JS, Sledge CB, editors, Kelley's Textbook of rheumatology. 7th edition. Elsevier Saunders, Philadelphia; 2005. p. 996-1042
   Google Scholar
• Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 2001;27(2):269-81
   PubMed Web of Science ®Google Scholar
• Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology 2000;39(1):28-33
   PubMed Web of Science ®Google Scholar
• Allaire SH, Prashker MJ, Meenan RF. The costs of rheumatoid-arthritis. Pharmacoeconomics 1994;6(6):513-22
   PubMed Web of Science ®Google Scholar
• Yelin E, Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum 1999;42(6):1209-18
   PubMed Web of Science ®Google Scholar
• Smolen JS, Breedveld FC, Eberl G, et al. Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. Arthritis Rheum 1995;38(1):38-43
   PubMed Web of Science ®Google Scholar
• Plenge RM, Padyukov L, Remmers EF, et al. Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. Am J Hum Genet 2005;77(6):1044-60
   PubMed Web of Science ®Google Scholar
• Zwerina J, Redlich K, Schett G, Smolen JS. Pathogenesis of rheumatoid arthritis: targeting cytokines. Ann NY Acad Sci 2005;1051:716-29
   PubMed Web of Science ®Google Scholar
• Redlich K, Hayer S, Ricci R, et al. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 2002;110(10):1419-27
   PubMed Web of Science ®Google Scholar
• O'Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med 2004;350:2591-602
   PubMed Web of Science ®Google Scholar
• Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232-5
   PubMedGoogle Scholar
• Morgan RW. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;341(18):1397; author reply 8-9
   PubMedGoogle Scholar
• Fitzgerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345:433-42
   PubMed Web of Science ®Google Scholar
• Silverstein FE, Faich G, Goldstein JL. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study. A randomized controlled trial. J Am Med Assoc 2000;284:1247-55
   PubMed Web of Science ®Google Scholar
• Bombardier C, Laine L, Reicin A. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8
   PubMed Web of Science ®Google Scholar
• Solomon DH. Selective cyclooxygenase 2 inhibitors and cardiovascular events. Arthritis Rheum 2005;52(7):1968-78
   PubMed Web of Science ®Google Scholar
• Wallace JL. Building a better aspirin: gaseous solutions to a century-old problem. Br J Pharmacol 2007;152(4):421-8
   PubMed Web of Science ®Google Scholar
• Transform Pharmaceuticals, Inc. Pharmaceutical compositions comprising a selective COX-2. WO2006058073; 2006
   Google Scholar
• Unigen Pharmaceuticals, Inc. Formulation of a mixture of free-B-ring flavonoids and flavans as a therapeutic agent. US2006177528; 2006
   Google Scholar
• Kirchner T, Aparicio B, Argentieri DC, et al. Effects of tepoxalin, a dual inhibitor of cyclooxygenase/5-lipoxygenase, on events associated with NSAID-induced gastrointestinal inflammation. Prostaglandins Leukot Essent Fatty Acids 1997;56(6):417-23
   PubMed Web of Science ®Google Scholar
• Celotti F, Laufer S. Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept. Pharmacol Res 2001;43(5):429-36
   PubMed Web of Science ®Google Scholar
• Altana Pharma AG. Combination of a NSAID and a PDE inhibitor. WO03024489; 2003
   Google Scholar
• Buttgereit F, Straub RH, Wehling M, Burmester GR. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum 2004;50(11):3408-17
   PubMed Web of Science ®Google Scholar
• Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002;96(1):23-43
   PubMed Web of Science ®Google Scholar
• Kirwan JR, Russell AS. Systemic glucocorticoid treatment in rheumatoid arthritis: a debate. Scand J Rheumatol 1998;27(4):247-51
   PubMedGoogle Scholar
• Laan RF, Jansen TL, Van Riel PL. Glucocorticosteroids in the management of rheumatoid arthritis. Rheumatology 1999;38(1):6-12
   PubMedGoogle Scholar
• Bijlsma JW, Boers M, Saag KG, Furst DE. Glucocorticoids in the treatment of early and late RA. Ann Rheum Dis 2003;62(11):1033-7
   PubMed Web of Science ®Google Scholar
• Van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, Bijlsma JW. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects. A randomized, double-blind, placebo-controlled clinical trial. Ann Int Med 2002;136(1):1-12
   PubMed Web of Science ®Google Scholar
• Kirwan JR, Bijlsma JW, Boers M, Shea BJ. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 2007;1:CD006356
   Google Scholar
• Jacobs JW, Van Everdingen AA, Verstappen SM, Bijlsma JW. Followup radiographic data on patients with rheumatoid arthritis who participated in a two-year trial of prednisone therapy or placebo. Arthritis Rheum 2006;54(5):1422-8
   PubMedGoogle Scholar
• De Bosscher K, Vanden Berghe W, Vermeulen L, et al. Glucocorticoids repress NF-kappaB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell. Proc Natl Acad Sci USA 2000;97(8):3919-24
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Adcock I. Anti-inflammatory actions of steroids: molecular mechanisms. Trends Pharmacol Sci 1993;14(12):436-41
   PubMed Web of Science ®Google Scholar
• Goodwin JS. Anti-inflammatory drugs. In: Sites DP, Terr AI, editor, Basic and clinical immunology. Los Altos, CA: Lange Medical Publications; 1994. p. 786-95
   Google Scholar
• Da Silva JA, Jacobs JW, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 2006;65(3):285-93
   PubMed Web of Science ®Google Scholar
• Reichardt HM, Tronche F, Berger S, et al. New insights into glucocorticoid and mineralocorticoid signaling: lessons from gene targeting. Adv Pharmacol 2000;47:1-21
   PubMedGoogle Scholar
• Reichardt HM, Schutz G. Glucocorticoid signalling: multiple variations of a common theme. Mol Cellular Endocrinol 1998;146(1-2):1-6
   PubMed Web of Science ®Google Scholar
• Kellendonk C, Tronche F, Reichardt HM, Schutz G. Mutagenesis of the glucocorticoid receptor in mice. J Steroid Biochem Mol Biol 1999;69(1-6):253-9
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci 1998;94(6):557-72
   PubMed Web of Science ®Google Scholar
• Cato AC, Wade E. Molecular mechanisms of anti-inflammatory action of glucocorticoids. Bioessays 1996;18(5):371-8
   PubMed Web of Science ®Google Scholar
• Karin M. New twists in gene regulation by glucocorticoid receptor: is DNA binding dispensable? Cell 1998;93(4):487-90
   PubMed Web of Science ®Google Scholar
• Schacke H, Schottelius A, Docke WD, et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci USA 2004;101(1):227-32
   PubMed Web of Science ®Google Scholar
• Coghlan MJ, Jacobson PB, Lane B, et al. A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects. Mol Endocrinol 2003;17(5):860-9
   PubMed Web of Science ®Google Scholar
• Koehler K, Liu Y, Pelcman B. Novel compounds. WO03082777; 2003
   Google Scholar
• Buttgereit F, Doering G, Schaeffler A, et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet 2008;371(9608):205-14
   PubMed Web of Science ®Google Scholar
• Tsakonas E, Fitzgerald AA, Fitzcharles MA, et al. Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3-year followup on the hydroxychloroquine in early rheumatoid arthritis (HERA) study. J Rheumatol 2000;27(3):623-9
   PubMed Web of Science ®Google Scholar
• Lard LR, Visser H, Speyer I, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001;111(6):446-51
   PubMed Web of Science ®Google Scholar
• Choi HK, Hernan MA, Seeger JD, et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359(9313):1173-7
   PubMed Web of Science ®Google Scholar
• Rommel C, Camps M, Ji H. PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat Rev 2007;7(3):191-201
   Google Scholar
• Wymann MP, Bulgarelli-Leva G, Zvelebil MJ, et al. Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol Cell Biol 1996;16(4):1722-33
   PubMed Web of Science ®Google Scholar
• Bayer Pharmaceutical Corp. Fused azole-pyrimidine derivatives exhibiting enhanced potency for phosphotidylinositol-3-kinase (P13K) inhibition. WO2004029055; 2004
   Google Scholar
• Bayer Pharmaceutical Corp. Fused azole-pyrimidine derivatives. US2006128732; 2006
   Google Scholar
• Martel-Pelletier J, Welsch DJ, Pelletier JP. Metalloproteases and inhibitors in arthritic diseases. Best Pract Res 2001;15(5):805-29
   Google Scholar
• Konttinen YT, Ainola M, Valleala H, et al. Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Ann Rheum Dis 1999;58(11):691-7
   PubMed Web of Science ®Google Scholar
• Dyax Corp. Metalloproteinase binding proteins. WO2007079218; 2007
   Google Scholar
• Itoh Y, Seiki M. MT1-MMP: a potent modifier of pericellular microenvironment. J Cellular Physiol 2006;206(1):1-8
   PubMed Web of Science ®Google Scholar
• Close DR. Matrix metalloproteinase inhibitors in rheumatic diseases. Ann Rheum Dis 2001;60(Suppl 3):iii62-7
   PubMed Web of Science ®Google Scholar
• Keystone E. Treatments no longer in development for rheumatoid arthritis. Ann Rheum Dis 2002;61(Suppl 2):ii43-5
   PubMedGoogle Scholar
• Levin JI. Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors. US20070155834; 2007
   Google Scholar
• Nakagawa TY, Brissette WH, Lira PD, et al. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity 1999;10(2):207-17
   PubMed Web of Science ®Google Scholar
• Bossard MJ, Tomaszek TA, Thompson SK, et al. Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification. J Biol Chem 1996;271(21):12517-24
   PubMed Web of Science ®Google Scholar
• Merck Frosst Canada, Ltd. Cathepsin cysteine protease inhibitors. WO2007003056; 2007
   Google Scholar
• Cai J, et al. 6-phenyl-1h-imidazo[4,5-c] pyridine-4-carbonitrile derivatives as cathepsin K and S inhibitors. WO2007080191; 2007
   Google Scholar
• Saltzman AG, et al. Use of cathepsin Z inhibitors for the treatment of rheumatoid arthritis and other autoimmune diseases. WO2005065693; 2005
   Google Scholar
• Scripps Research, Inst. Treatment of degenerative cartilage conditions in a mammal with glycosidase inhibitors. US2007197471; 2007
   Google Scholar
• Ortutay Z, Polgar A, Gomor B, et al. Synovial fluid exoglycosidases are predictors of rheumatoid arthritis and are effective in cartilage glycosaminoglycan depletion. Arthritis Rheum 2003;48(8):2163-72
   PubMedGoogle Scholar
• Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344(12):907-16
   PubMed Web of Science ®Google Scholar
• Butler DM, Maini RN, Feldmann M, Brennan FM. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti-TNF-alpha antibody with the interleukin-1 receptor antagonist. Eur Cytokine Netw 1995;6(4):225-30
   PubMed Web of Science ®Google Scholar
• Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343(22):1586-93
   PubMed Web of Science ®Google Scholar
• Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130(6):478-86
   PubMed Web of Science ®Google Scholar
• Klareskog L, Van Der Heijde D, De Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363(9410):675-81
   PubMed Web of Science ®Google Scholar
• Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology 2003;42(5):617-21
   PubMed Web of Science ®Google Scholar
• Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002;46(10):2565-70
   PubMed Web of Science ®Google Scholar
• Nakelchik M, Mangino JE. Reactivation of histoplasmosis after treatment with infliximab. Am J Med 2002;112(1):78
   PubMed Web of Science ®Google Scholar
• Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002;46(12):3151-8
   PubMed Web of Science ®Google Scholar
• Askling J, Fored CM, Brandt L, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005;64(10):1421-6
   PubMed Web of Science ®Google Scholar
• Askling J, Fored CM, Baecklund E, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005;64(10):1414-20
   PubMed Web of Science ®Google Scholar
• Baecklund E, Ekbom A, Sparen P, et al. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 1998;317(7152):180-1
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007;56(9):2886-95
   PubMed Web of Science ®Google Scholar
• Bresnihan B, Cunnane G. Interleukin-1 receptor antagonist. Rheum Dis Clin North Am 1998;24(3):615-28
   PubMed Web of Science ®Google Scholar
• Nixon R, Bansback N, Brennan A. The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons. Rheumatology 2007;46(7):1140-7
   PubMed Web of Science ®Google Scholar
• Cron RQ. A signal achievement in the treatment of arthritis. Arthritis Rheum 2005;52(8):2229-32
   PubMed Web of Science ®Google Scholar
• Medical News Today: Actemra™ (tocilizumab) significantly improves symptoms of rheumatoid arthritis compared to a current standard of care. Available from: www.medicalnewstoday.com/articles/74401.php [Last accessed 22 May 2008]
   Google Scholar
• Ryter SW, Otterbein LE. Carbon monoxide in biology and medicine. Bioessays 2004;26(3):270-80
   PubMed Web of Science ®Google Scholar
• Motterlini RA, Mann BE. Therapeutic delivery of carbon monoxide. WO02092075; 2002
   Google Scholar
• Sangstat Medical, Corp. Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders. WO02078684; 2002
   Google Scholar
• Motterlini RA, Mann BE. Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs. WO2004045598; 2004
   Google Scholar
• Motterlini RA, Mann BE. Therapeutic delivery of carbon monoxide. WO2008003953; 2008
   Google Scholar
• Alfama, Inc. Method for treating a mammal by administration of a compound having the ability to release CO, compounds having the ability to release CO and pharmaceutical compositions thereof. US2004067261; 2004
   Google Scholar
• Alfama, Inc. Molybdenum carbonyl complexes for treating rheumatoid arthritis and other inflammatory diseases. WO2007073225; 2007
   Google Scholar
• US Government. Amelioration of inflammatory arthritis by targeting the pre-ligand assembly domain (PLAD) of tumor necrosis factor receptors. WO2007002633; 2007
   Google Scholar
• Gopalakrishnakone P, Thwin M, Sato K. Methods and compositions for treatment of arthritis and cancer. US2007037253; 2007
   Google Scholar
• Gopalakrishnakone P, Thwin M, Ong W. Phospholipase A2-inhibitory peptide with anti-arthritic and neuroprotective activities. US2005069530; 2005
   Google Scholar
• Murakami M, Kudo I. Phospholipase A2. J Biochem 2002;131(3):285-92
   PubMed Web of Science ®Google Scholar
• Cirino G, Cicala C, Sorrentino L, et al. Recombinant secreted nonpancreatic phospholipase A2 induces a synovitis-like inflammation in the rat air pouch. J Rheumatol 1994;21(5):824-9
   PubMedGoogle Scholar
• Jamal OS, Conaghan PG, Cunningham AM, et al. Increased expression of human type IIa secretory phospholipase A2 antigen in arthritic synovium. Ann Rheum Dis 1998;57(9):550-8
   PubMedGoogle Scholar
• Lin MK, Katz A, Van Den Bosch H, et al. Induction of secretory phospholipase A2 confirms the systemic inflammatory nature of adjuvant arthritis. Inflammation 1998;22(2):161-73
   PubMedGoogle Scholar
• Bradley JD, Dmitrienko AA, Kivitz AJ, et al. A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis. J Rheumatol 2005;32(3):417-23
   PubMed Web of Science ®Google Scholar
• Yeo KT, Wang HH, Nagy JA, et al. Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. Cancer Res 1993;53(12):2912-8
   PubMed Web of Science ®Google Scholar
• Sone H, Kawakami Y, Sakauchi M, et al. Neutralization of vascular endothelial growth factor prevents collagen-induced arthritis and ameliorates established disease in mice. Biochem Biophys Res Commun 2001;281(2):562-8
   PubMed Web of Science ®Google Scholar
• Lg Life Sciences, Ltd. Novel inhibitors of protein kinase. WO2007058482; 2007
   Google Scholar
• Hennequin LF. Quinazoline compounds. US2005085465; 2005
   Google Scholar
• Hennequin LF. Quinazoline compounds. WO03064413; 2003
   Google Scholar
• Godessart N. Chemokine receptors: attractive targets for drug discovery. Ann NY Acad Sci 2005;1051:647-57
   PubMed Web of Science ®Google Scholar
• Zapico I, Coto E, Rodriguez A, et al. CCR5 (chemokine receptor-5) DNA-polymorphism influences the severity of rheumatoid arthritis. Genes Immunity 2000;1(4):288-9
   PubMed Web of Science ®Google Scholar
• Schering, Corp. Piperazine derivatives useful as CCR5 antagonists. WO2007050375; 2007
   Google Scholar
• Schering, Corp. CCR5 antagonists useful for treating HIV. WO2007100739; 2007
   Google Scholar
• Schering, Corp. CCR5 antagonists useful for treating HIV. US20070203149; 2007
   Google Scholar
• Amgen, Inc. CXCR3 antagonists. US20070149557; 2007
   Google Scholar
• Arena Pharmaceuticals, Inc. Human g protein-coupled receptor and modulators thereof for the treatment of inflammatory disorders. US20070160987; 2007
   Google Scholar
• Carter PH. Lactams of alkylated acyclic diamine derivatives as modulators of chemokine receptor activity. US20070197516; 2007
   Google Scholar
• Carter P. Malonamides and malonamide derivatives as modulators of chemokine receptor activity. US20070213379; 2007
   Google Scholar
• Koch AE, Kunkel SL, Harlow LA, et al. Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J Clin Invest 1992;90(3):772-9
   PubMed Web of Science ®Google Scholar
• Youssef S, Maor G, Wildbaum G, et al. C-C chemokine-encoding DNA vaccines enhance breakdown of tolerance to their gene products and treat ongoing adjuvant arthritis. J Clin Invest 2000;106(3):361-71
   PubMed Web of Science ®Google Scholar
• Ogata H, Takeya M, Yoshimura T, et al. The role of monocyte chemoattractant protein-1 (MCP-1) in the pathogenesis of collagen-induced arthritis in rats. J Pathol 1997;182(1):106-14
   PubMed Web of Science ®Google Scholar
• Warner-Lambert, Co. Inhibitors of colony stimulating factors. US2007059280; 2007
   Google Scholar
• Devalaraja MN, et al. Inhibitors of colony stimulating factors. US2002141994; 2002
   Google Scholar
• Mauri C, Chu CQ, Woodrow D, et al. Treatment of a newly established transgenic model of chronic arthritis with nondepleting anti-CD4 monoclonal antibody. J Immunol 1997;159(10):5032-41
   PubMed Web of Science ®Google Scholar
• Choy EH, Panayi GS, Emery P, et al. Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo-controlled trial. Rheumatology 2002;41(10):1142-8
   PubMedGoogle Scholar
• ISIS Innovation. Treatment of chronic joint inflammation by an anti-CD3 antibody. EP1803466; 2007
   Google Scholar
• Hindmarsh EJ, Staykova MA, Willenborg DO, Parish CR. Cell surface expression of the 300 kDa mannose-6-phosphate receptor by activated T lymphocytes. Immunol Cell Biol 2001;79(5):436-43
   PubMedGoogle Scholar
• Pharmaxix Pty Ltd. Mannose-6-phosphonate compounds for the treatment of inflammatory diseases. US2007082850; 2007
   Google Scholar
• Warner-Lambert, Co. Combination therapies utilizing benzamide inhibitors of the P2X7 receptors. WO2006003517; 2006
   Google Scholar
• Warner-Lambert, Co. Combination therapies utilizing benzamide inhibitors of the P2X7 receptors. EP1763353; 2007
   Google Scholar
• Bernatchez-Lemaire I. Use of histogranin and histogranin-like compounds as inhibitors of P2X7 receptor function and as anti-arthritic agents. WO2007025366; 2007
   Google Scholar
• Dell'Antonio G, Quattrini A, Cin ED, et al. Relief of inflammatory pain in rats by local use of the selective P2X7 ATP receptor inhibitor, oxidized ATP. Arthritis Rheum 2002;46(12):3378-85
   PubMed Web of Science ®Google Scholar
• Labasi JM, Petrushova N, Donovan C, et al. Absence of the P2X7 receptor alters leukocyte function and attenuates an inflammatory response. J Immunol 2002;168(12):6436-45
   PubMed Web of Science ®Google Scholar
• Dana Farber Cancer Inst, Inc. VLA proteins. EP0330506; 1989
   Google Scholar
• Wyeth, Corp. Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4. US2007099921; 2007
   Google Scholar
• Elan Pharm, Inc. Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha-4 integrins. US2007027131; 2007
   Google Scholar
• Wyeth, Corp. Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by VLA-4. US2007142416; 2007
   Google Scholar
• Merck & Co, Inc. Vla-4 antagonists. US2007179190; 2007
   Google Scholar
• Litzenburger T, et al. Anti-ICAM-1 human antibodies and uses thereof. WO2005086568; 2005
   Google Scholar
• Schett G, Tohidast-Akrad M, Smolen JS, et al. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum 2000;43(11):2501-12
   PubMed Web of Science ®Google Scholar
• Merck & Co, Inc. P38 kinase inhibiting agents. WO2007067478; 2007
   Google Scholar
• Merck & Co, Inc. Heterobicyclic compounds useful as P38 kinase inhibiting agents. WO2007021710; 2007
   Google Scholar
• University California. Methods of ameliorating arthritis by modulating JNK signalsome activity. WO03023362; 2003
   Google Scholar
• Firestein GS. Methods of ameliorating arthritis by modulating JNK signalsome activity. US2003068660; 2003
   Google Scholar
• Signal Pharm, Inc. Anthrone derivatives and their use as JNK inhibitors. EP1363891; 2003
   Google Scholar
• Sakata ST, et al. Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof a JNK inhibitors and compositions and methods related thereto. US2006004080; 2006
   Google Scholar
• Lubberts E, Koenders MI, Van Den Berg WB. The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res Ther 2005;7(1):29-37
   PubMed Web of Science ®Google Scholar
• Cooley Godward Kronish LLP. Compounds. US20080044423; 2008
   Google Scholar
• Cooper & Dunham LLP. Suppression of TNF alpha and IL-12 in therapy. US20070178099; 2007
   Google Scholar
• Zymogenetics, Inc. Methods of treating autoimmune diseases using IL-21. US2007048265; 2007
   Google Scholar
• Osteologix, Inc. A method of improving treatments in rheumatoid and arthritic diseases. WO2005123193; 2005
   Google Scholar
• Osteologix, Inc. Treatments comprising strontium for rheumatic and arthritic diseases and pain. EP1758653; 2007
   Google Scholar
• Bernstein LR. Gallium complexes of 3-hydroxy-4-pyrones to treat or prevent bone disease. US5998397; 1999
   Google Scholar
• Ohio University. Method of treating arthritis using gallium compounds. US5175006; 1992
   Google Scholar
• Titan Pharmaceuticals, Inc. Use of gallium to treat inflammatory arthritis. WO2005058331; 2005
   Google Scholar
• Titan Pharmaceuticals, Inc. Use of gallium to treat inflammatory arthritis. EP1694341; 2006
   Google Scholar
• Jones Day. Chronic articular inflammation-modulating composition based on collagen-polyvinylpyrrolidone. US20070172445; 2007
   Google Scholar
• Wang D, Miller SC, Liu XM, et al. Novel dexamethasone-HPMA copolymer conjugate and its potential application in treatment of rheumatoid arthritis. Arthritis Res Ther 2007;9(1):R2
   PubMed Web of Science ®Google Scholar
• Wang D, Kopec ˇek J, Miller SC, et al. Macromolecular delivery systems for non-invasive imaging, evaluation and treatment of arthritis and other inflammatory diseases. WO2005097073; 2005
   Google Scholar
• Koning GA, Schiffelers RM, Wauben MH, et al. Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate-containing RGD peptide liposomes inhibits experimental arthritis. Arthritis Rheum 2006;54(4):1198-208
   PubMed Web of Science ®Google Scholar
• Metselaar JM, Van Den Berg WB, Holthuysen AE, et al. Liposomal targeting of glucocorticoids to synovial lining cells strongly increases therapeutic benefit in collagen type II arthritis. Ann Rheum Dis 2004;63(4):348-53
   PubMed Web of Science ®Google Scholar
• Barenholz Y, Naparstek Y, Avnir Y, et al. Use of liposomal glucocorticoids for treating inflammatory states. WO2006027786; 2006
   Google Scholar
• Barenholz Y, Gabizon AA, Avnir Y. Liposomal compositions of glucocorticoid and glucocorticoid derivatives. WO2006027787; 2006
   Google Scholar